Supporting the

Neuroendocrine Cancer Community

NICE approves Avelumab

NICE approves Avelumab

21st APRIL NICE APPROVES AVELUMAB Neuroendocrine Cancer UK is delighted to share with you NICE’s approval of Avelumab as a first line therapy option in metastatic MCC.  Avelumab is now recommended as an option for treating metastatic Merkel cell carcinoma in adults...